Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07684495
Starting soon Not applicable

Aerobic Exercises Versus Sub Occipital Myofascial Release on Memory Function in Females With Premenstrual Syndrome.

NCT07684495 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-07-03
Last updated
2026-07-06

Condition(s) studied

Premenstrual Syndrome

Investigational drug(s) / intervention(s)

Aerobic exerciseSub occipital myofascial release

Aerobic exercise: A moderate-intensity aerobic exercise session on a treadmill consists of three phases: warm-up, active phase, and cool-down. The warm-up lasts 5-10 minutes and involves walking at minimum speed (2.0 - 3.0 km/h) with a slight incline (1 -2%) or as tolerated. The active phase, lasting 20-30 minutes, maintains a brisk walking or light jogging pace with moderate speed (4.5-6.5 km/h) or as tolerated. This phase can include steady-state jogging or intervals of walking and jogging to sustain cardiovascular engagement. Finally, the cool-down phase lasts 5-10 minutes, where the speed is gradually reduced to 2.0 - 3.0 km/h, allowing the heart rate to decrease safely.

Sub occipital myofascial release: The patient will be asked to take a supine position, and a pillow will be placed under the patient's head for comfort until starting the procedure, the patient will be instructed to be relaxed, then the therapist will sit at the head of the bed and will place both hands underneath the patient's head in the occipital region. The therapist should then feel for the occipital ridge along the scalp and move the hands slightly caudal until the muscle is felt. The therapist then will flex the fingers upward against the suboccipital muscles and this position will be hold for 3 to 5 minutes or until significant muscle tension will be released.

Study summary

This study will be conducted to investigate the effect of aerobic exercises versus sub occipital Myofascial release on memory functions in females with premenstrual syndrome.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
30 Years
Healthy volunteers
No
Inclusion Criteria: Females with premenstrual syndrome and memory function deficits have to meet the following criteria in order to participate in this study: * Their age ranged from 18 to 30 years old. * Their body mass index (BMI) ranged from 18.5 - 30 kg/cm2. Exclusion Criteria: * Any medications that can affect central nervous system or memory function. * Any neurological disorders affect their memory function. * Pregnant women. * Daily smokers. * Had a concussion or head trauma within the past 30 days. * Took any illegal drugs or alcohol within the past 30 days.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Gehad Mohamed Ali Hurghada Egypt

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07684495 on ClinicalTrials.gov ↗ ← All trials in Egypt